Rufinamide in patients with Lennox-Gastaut syndrome

References

• Gastaut H, Roger J, Soulayrol R, et al. Childhood epileptic encephalopathy with diffuse slow spike-waves (otherwise known as “petit mal variant”) or Lennox syndrome. Epilepsia. 1966;7(2):139–179.
   PubMedGoogle Scholar
• Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82–93.
   PubMed Web of Science ®Google Scholar
• Goldsmith IL, Zupanc ML, Buchhalter JR. Long-term seizure outcome in 74 patients with Lennox-Gastaut syndrome: effects of incorporating MRI head imaging in defining the cryptogenic subgroup. Epilepsia. 2000;41(4):395–399.
   PubMed Web of Science ®Google Scholar
• Hancock EC, Cross JH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2013;2:CD003277.
   Google Scholar
• Berg AT, Millichap JJ. The 2010 revised classification of seizures and epilepsy. Continuum (Minneap Minn). 2013;19(3 Epilepsy):571–597.
   Google Scholar
• van Rijckevorsel K. Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat. 2008;4(6):1001–1019.
   PubMedGoogle Scholar
• Genton P, Guerrini R, Dravet C. The Lennox-Gastaut syndrome. In: Meinardi H, editor. Handbook of Clinical Neurology. 29th ed. Amsterdam: Elsevier Science B.V.; 2000:211–222.
   Google Scholar
• Kramer U, Nevo Y, Neufeld MY, Fatal A, Leitner Y, Harel S. Epidemiology of epilepsy in childhood: a cohort of 440 consecutive patients. Pediatr Neurol. 1998;18(1):46–50.
   PubMed Web of Science ®Google Scholar
• Trevathan E, Murphy CC, Yeargin-Allsopp M. Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children. Epilepsia. 1997;38(12):1283–1288.
   PubMed Web of Science ®Google Scholar
• Roger J, Remy C, Bureau M, Oller-Daurella L, Beaumanoir A, Favel P, Dravet C. Le syndrome de Lennox-Gastaut de l’adulte [Lennox-Gastaut syndrome in the adult]. Rev Neurol (Paris). 1987;143(5):401–405. French.
   PubMed Web of Science ®Google Scholar
• Camfield P, Camfield C. Long-term prognosis for symptomatic (secondarily) generalized epilepsies: a population-based study. Epilepsia. 2007;48(6):1128–1132.
   PubMed Web of Science ®Google Scholar
• Camfield C, Camfield P. Twenty years after childhood-onset symptomatic generalized epilepsy the social outcome is usually dependency or death: a population-based study. Dev Med Child Neurol. 2008;50(11):859–863.
   PubMed Web of Science ®Google Scholar
• Crumrine PK. Lennox-Gastaut syndrome. J Child Neurol. 2002; 17(Suppl 1):S70–S75.
   Google Scholar
• Gallop K, Wild D, Verdian L, et al. Lennox-Gastaut syndrome (LGS): development of conceptual models of health-related quality of life (HRQL) for caregivers and children. Seizure. 2010;19(1):23–30.
   PubMed Web of Science ®Google Scholar
• Skornicki M, Clements KM, O’Sullivan AK. Budget impact analysis of antiepileptic drugs for Lennox-Gastaut syndrome. J Manag Care Spec Pharm. 2014;20(4):400–406.
   PubMed Web of Science ®Google Scholar
• Camfield PR. Definition and natural history of Lennox-Gastaut syndrome. Epilepsia. 2011;52(Suppl 5):3–9.
   PubMed Web of Science ®Google Scholar
• Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia. 2010;51(4):676–685.
   PubMed Web of Science ®Google Scholar
• Autry AR, Trevathan E, Van Naarden Braun K, Yeargin-Allsopp M. Increased risk of death among children with Lennox-Gastaut syndrome and infantile spasms. J Child Neurol. 2010;25(4):441–447.
   PubMed Web of Science ®Google Scholar
• Beaumanoir A, Blume W. The Lennox-Gastaut syndrome. In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, editors. Epileptic Syndromes in Infancy, Childhood and Adolescence. 4th ed. Paris, France: John Libbey Eurotext Ltd; 2005:125–148.
   Google Scholar
• Kerr M, Kluger G, Philip S. Evolution and management of Lennox-Gastaut syndrome through adolescence and into adulthood: are seizures always the primary issue? Epileptic Disord. 2011;13(Suppl 1): S15–S26.
   Google Scholar
• Berg AT, Nickels K, Wirrell EC, et al. Mortality risks in new-onset childhood epilepsy. Pediatrics. 2013;132(1):124–131.
   PubMed Web of Science ®Google Scholar
• Gallop K, Wild D, Nixon A, Verdian L, Cramer JA. Impact of Lennox-Gastaut syndrome (LGS) on health-related quality of life (HRQL) of patients and caregivers: literature review. Seizure. 2009;18(8): 554–558.
   PubMed Web of Science ®Google Scholar
• Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008;70(21):1950–1958.
   PubMed Web of Science ®Google Scholar
• Kluger G, Glauser T, Krauss G, Seeruthun R, Perdomo C, Arroyo S. Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand. 2010;122(3): 202–208.
   PubMed Web of Science ®Google Scholar
• Hopkins J, Irvine F. Qualitative insights into the role and practice of epilepsy specialist nurses in England: a focus group study. J Adv Nurs. 2012;68(11):2443–2453.
   PubMed Web of Science ®Google Scholar
• Benbadis SR, Sheth RD. Advances in identifying and treating Lennox-Gastaut syndrome: do you know LGS when you see it? Neurol Rev. 2012;(Suppl):S1–S8.
   Google Scholar
• Epilepsy Foundation Website. Lennox-Gastaut Syndrome (LGS). 2014. Available from: http://www.epilepsy.com/learn/types-epilepsysyndromes/lennox-gastaut-syndrome-lgs. Accessed February 1, 2016.
   Google Scholar
• Carmant L, Whiting S. Lennox-Gastaut syndrome: an update on treatment. Can J Neurol Sci. 2012;39(6):702–711.
   PubMed Web of Science ®Google Scholar
• BANZEL (rufinamide) Prescribing Information. Woodcliff Lake (NJ): Eisai Inc.; 2015.
   Google Scholar
• Appleton RE. Vigabatrin in the management of generalized seizures in children. Seizure. 1995;4(1):45–48.
   PubMedGoogle Scholar
• Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49(7):1123–1141.
   PubMed Web of Science ®Google Scholar
• Epilepsy Foundation Website 2015. Rufinamide. Available from: http://www.epilepsy.com/medications/rufinamide/advanced. Accessed February 1, 2016.
   Google Scholar
• Elger CE, Stefan H, Mann A, Narurkar M, Sun Y, Perdomo C. A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res. 2010;88(2–3):255–263.
   PubMed Web of Science ®Google Scholar
• Biton V, Krauss G, Vasquez-Santana B, Bibbiani F, Mann A, Perdomo C, Narurkar M. A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia. 2011;52(2):234–242.
   PubMed Web of Science ®Google Scholar
• Wisniewski CS. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with Lennox-Gastaut syndrome. Ann Pharmacother. 2010;44(4):658–667.
   PubMed Web of Science ®Google Scholar
• McClean M, Schmutz M, Pozza M, Wamil M. The influence of rufinamide on sodium currents and action potential firing in rodent neurons. In: Abstracts from the joint annual meeting of the American Epilepsy Society and the American Clinical Neurophysiology Society. Washington, DC, USA, December 2–6, 2005. Abstract 3.062. Epilepsia. 2005;46(Suppl 8):1–373.
   Google Scholar
• Critchley DJ, Aluri J, Boyd P, Whayman M, Narurkar M, Delargy H, Bibbiani F. Bioavailability of three rufinamide oral suspensions compared with the marketed 400-mg tablet formulation: results from a randomized-sequence, open-label, four-period, four-sequence crossover study in healthy subjects. Clin Ther. 2011;33(1): 146–157.
   PubMed Web of Science ®Google Scholar
• la Marca G, Rosati A, Falchi M, Malvagia S, Della Bona ML, Pellacani S, Guerrini R. A pharmacokinetic study and correlation with clinical response of rufinamide in infants with epileptic encephalopathies. Pharmacology. 2013;91(5–6):275–280.
   PubMed Web of Science ®Google Scholar
• Inovelon Tablets and Oral Suspension Summary of Product Characteristics. Hatfield, Hertfordshire, UK: Eisai Ltd.; 2013.
   Google Scholar
• Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K. Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Res. 2014;108(9):1627–1636.
   PubMed Web of Science ®Google Scholar
• Palhagen S, Canger R, Henriksen O, van Parys JA, Riviere ME, Karolchyk MA. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Res. 2001;43(2): 115–124.
   PubMed Web of Science ®Google Scholar
• Loscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia. 2006;47(8):1253–1284.
   PubMed Web of Science ®Google Scholar
• Gayatri NA, Livingston JH. Aggravation of epilepsy by anti-epileptic drugs. Dev Med Child Neurol. 2006;48(5):394–398.
   PubMed Web of Science ®Google Scholar
• Coppola G, Grosso S, Franzoni E, et al. Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience. Seizure. 2010;19(9):587–591.
   PubMed Web of Science ®Google Scholar
• Kluger G, Haberlandt E, Kurlemann G, et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav. 2010;17(4):546–548.
   PubMed Web of Science ®Google Scholar
• Kluger G, Kurlemann G, Haberlandt E, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav. 2009;14(3): 491–495.
   PubMed Web of Science ®Google Scholar
• Vendrame M, Loddenkemper T, Gooty VD, et al. Experience with rufinamide in a pediatric population: a single center’s experience. Pediatr Neurol. 2010;43(3):155–158.
   PubMed Web of Science ®Google Scholar
• Kessler SK, McCarthy A, Cnaan A, Dlugos DJ. Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox-Gastaut Syndrome. Epilepsy Res. 2015;112:18–26.
   PubMed Web of Science ®Google Scholar
• Coppola G, Besag F, Cusmai R, et al. Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines. Eur J Paediatr Neurol. 2014;18(6):685–690.
   PubMed Web of Science ®Google Scholar
• Arzimanoglou A, Ferreira JA, Satlin A, et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study. Eur J Paediatr Neurol. 2016;20(3):393–402.
   PubMed Web of Science ®Google Scholar
• Schimpf R, Veltmann C, Papavassiliu T, et al. Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm. 2012;9(5):776–781.
   PubMed Web of Science ®Google Scholar
• Gibson PA. Resources for caregivers and families of patients with Lennox-Gastaut syndrome. Epilepsia. 2014;55(Suppl 4):34–36.
   PubMedGoogle Scholar
• Gibson PA. Lennox-Gastaut syndrome: impact on the caregivers and families of patients. J Multidiscip Healthc. 2014;7:441–448.
   PubMedGoogle Scholar
• Schachter SC, Sirven JI. Vagus Nerve Stimulation (VNS). Epilepsy Foundation Website; 2013. Available from: www.epilepsy.com/learn/treating-seizures-and-epilepsy/devices/vagus-nerve-stimulation-vns. Accessed February 1, 2016.
   Google Scholar
• LGS Foundatio. Website. Available from: http://www.lgsfoundation.org/. Accessed February 1, 2016.
   Google Scholar
• Epilepsy Foundation Website. Available from: http://www.epilepsy.com. Accessed February 1, 2016.
   Google Scholar
• Citizens United for Research in Epilepsy (CURE) Website. Available from: http://www.cureepilepsy.org/aboutCURE/. Accessed February 1, 2016.
   Google Scholar
• Wake Forest Baptist Health Website. Available from: http://www.wakehealth.edu/Neurosciences/Comprehensive-Epilepsy-Center/Epilepsy-Resources.htm. Accessed February 1, 2016.
   Google Scholar
• Child Neurology Foundation Website. Available from: http://www.childneurologyfoundation.org/. Accessed February 1, 2016.
   Google Scholar
• Child Neurology Society Website. Available from: http://www.childneurologysociety.org/. Accessed February 1, 2016.
   Google Scholar
• The Charlie Foundation for Ketogenic Therapies Website. Available from: http://www.charliefoundation.org/. Accessed February 1, 2016.
   Google Scholar
• Family Caregiver Alliance Website. Available from: https://www.caregiver.org/. Accessed February 1, 2016.
   Google Scholar
• National Alliance for Caregiving Website. Available from: http://www.caregiving.org/. Accessed February 1, 2016.
   Google Scholar
• BANZEL (rufinamide) Website. Available from: https://www.banzel.com/. Accessed February 1, 2016.
   Google Scholar